Nvidia will open Cambridge-1 supercomputing to UK healthcare startups

by ddos ·

At present, the most powerful supercomputer in the UK is Cambridge-1. This is a $100 million project invested by NVIDIA. It will be committed to promoting the development of the medical industry. Researchers and scientists can use artificial intelligence to accelerate biological research. Nvidia has already cooperated with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore Technologies. The first batch of projects includes an in-depth understanding of brain diseases such as dementia, the use of artificial intelligence to assist in the development of new drugs, and the improvement of the accuracy of research on finding pathogenic variants in the human genome.

Cambridge-1 supercomputer

Image: Nvidia

Recently, following the 10-year plan to promote the research and implementation of artificial intelligence technology in the United Kingdom, NVIDIA announced that it will open the Cambridge-1 supercomputer to UK healthcare startups. David Hogan, vice president of Enterprise EMEA at NVIDIA, said, “Today is an important step in furthering the U.K.’s strategic advantage as a global leader in AI. NVIDIA is proud to support the U.K.’s AI ecosystem with Cambridge-1, the country’s most powerful supercomputer, and our Inception programme that includes more than 500 of the U.K.’s most dynamic AI startups.”

Peptone, a biotechnology company in the UK and a member of NVIDIA Inception, will be assisted by the Cambridge-1 supercomputer. Peptone is planning to use supercomputers to meet its challenges in the field of digital biology and is currently creating a protein engineering system. Combining generative artificial intelligence models and computational molecular physics to discover therapies for inflammatory diseases such as chronic obstructive pulmonary disease, psoriasis, and asthma.

“Access to the compute power of Cambridge-1 will be a game changer in our effort to fuse computation with laboratory experiments to change the way protein drugs are engineered,” said Dr. Kamil Tamiola, Peptone CEO and founder. “We plan to use Cambridge-1 to vastly improve the design of antibodies to help treat numerous inflammatory diseases.”

Every start-up company that uses NVIDIA Inception is supported during its company life cycle and will allow its platform to go public and develop. At present, these start-up companies can submit applications before the end of the year, and NVIDIA will make an announcement after being selected, and the list is expected to be announced in early 2022.

Tags: Cambridge-1NVIDIA Inception